TNFRSF17 and plasma cell myeloma: In a separate study, Lam et al., designed an anti-BCMA CAR (FHVH33-CD8BBξ) with a fully human heavy-chain variable domain (FHVH) to circumvent anti-CAR immune responses in r/r multiple myeloma as discussed above.